The Carlsbad facility brings end-to-end viral vector solutions and aseptic fill-finish capabilities to Lonza, catering specifically to the burgeoning cell and gene therapy market. This strategic acquisition of five specialized contract development and manufacturing organization (CDMO) sites from
Institutional investors now manage portfolios by treating inadequate environmental, social, and governance strategies as material financial liabilities rather than mere corporate social responsibility gestures. This seismic shift marks the end of an era where pharmaceutical companies could rely on
Siloed data across quality, manufacturing, and post-market surveillance prevents manufacturers from seeing the cross-functional impacts that regulatory AI tools now identify instantly. The medical device industry is currently navigating a period of unprecedented transformation, where the
A dual-sourcing strategy ensures that the pursuit of environmental milestones does not compromise the security of the supply chain for essential medical treatments. As global healthcare systems face unprecedented demand, the pharmaceutical industry is increasingly pressured to harmonize life-saving
FDA released final guidance Monday explaining how developers of cell-based and gene-based treatments should demonstrate potency, meaning the biological activity a treatment needs to have its intended effect. Developers should start checking potency early during development and keep checking as
Ethiopia's strategy reflects a broader continental trend toward health security, where local production is viewed as the only viable path to effective public health response. By 2030, the nation intends to transition from a major importer of medical goods to a self-reliant manufacturing powerhouse,